Semler Scientific, Inc. (SMLR)
NASDAQ: SMLR · Real-Time Price · USD
35.66
+0.79 (2.27%)
At close: Aug 6, 2025, 4:00 PM
35.88
+0.22 (0.62%)
After-hours: Aug 6, 2025, 7:51 PM EDT

Company Description

Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States.

The company’s products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient’s vascular condition.

The company’s products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers.

It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.

Semler Scientific, Inc.
Semler Scientific logo
CountryUnited States
Founded2007
IPO DateFeb 21, 2014
IndustryMedical Devices
SectorHealthcare
Employees79
CEODouglas Murphy-Chutorian

Contact Details

Address:
2340-2348 Walsh Avenue, Suite 2344
Santa Clara, California 95051
United States
Phone877 774 4211
Websitesemlerscientific.com

Stock Details

Ticker SymbolSMLR
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001554859
CUSIP Number81684M104
ISIN NumberUS81684M1045
Employer ID26-1367393
SIC Code3845

Key Executives

NamePosition
Dr. Douglas Murphy-Chutorian M.D.Chief Executive Officer, President and Director
Eric H. SemlerExecutive Chairman of the Board
Renae CormierChief Financial Officer, Head of Corporate Communications and Business Strategy and Secretary
Dr. Herbert J. Semler F.A.C.C., F.A.C.P, F.A.H., F.S.C.A.I., J.S., M.D.Founder and Chairman Emeritus
Shane ReidChief Technology Officer
Cindy GuinassoSenior Vice President of Business Development

Latest SEC Filings

DateTypeTitle
Aug 4, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Aug 4, 202510-QQuarterly Report
Aug 4, 20258-KCurrent Report
Jul 24, 20258-KCurrent Report
Jul 17, 2025ARSFiling
Jul 17, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Jul 17, 2025DEF 14AOther definitive proxy statements
Jul 17, 20258-KCurrent Report
Jul 16, 2025SCHEDULE 13G/AFiling
Jul 16, 2025SCHEDULE 13GFiling